Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Costimulatory Bispecific Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD28 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD28 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD28 Products |
| Gene Delivery | CD28 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD28 Products |
| Benchmark Ab | Anti-CD28 Recombinant positive control. |
View CD28 Products |
| Validator | CD28 siRNA Set For knockdown verification. |
View CD28 Products |
| Related Target A | CD80 Endogenous primary ligand for CD28, essential for binding competition assays. |
View CD80 Products |
| Related Target B | CTLA4 Inhibitory homolog for target selectivity and off-target screening. |
View CTLA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, Sequence Verified |
| Affinity tuning for bispecifics | Strictly HEK293 Expressed (Native Glycosylation) ECD-Fc for accurate SPR/BLI kinetics |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD28 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD28 therapeutics is intensifying, with major players shifting focus from traditional mAbs (due to historical toxicity concerns) to Tumor-Targeted Costimulatory Bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting conditionally active biologics (masked antibodies) and engineered dual-targeting constructs that decouple systemic immune activation from localized tumor eradication.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific (Costimulatory) | Regeneron, Sanofi | Prostate Cancer, Ovarian Cancer | Affinity Tuning Assay (Need high-purity ECD-Fc) |
| Conditionally Active (Masked) | Janux, Amunix | Solid Tumors | Cleavage Release Validation (Native Glycosylated Proteins) |
| Cell Therapy (CAR-T) | Novartis, Gilead | Hematologic Malignancies | Extracellular Domain Profiling (Theoretical MW confirmed) |